GENEDX HOLDINGS CORP (WGS) Stock News
NASDAQ:WGS - Nasdaq - US81663L2007 - Common Stock - Currency: USD
WGS Latest News, Press Relases and Analysis
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx...
INVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the Firm
/PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ:...
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx...
The Joint Misses Q1 Earnings Estimates on Rising Expenses
JYNT expects to open 30-40 franchised clinics in 2025, down from 57 last year.
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
Here's Why You Should Hold Cigna Stock in Your Portfolio for Now
CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.
Danaher Partners With AstraZeneca to Support Precision Medicine
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Why Investors Were Avoiding GeneDx Holdings Stock This Week
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why Encompass Health Shares Are Attracting Investors Now
EHC stock jumps 28.8% YTD as investors rally behind strong earnings beat, raised 2025 guidance and a growing national rehab hospital footprint.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates
BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.
GeneDx to Participate in Upcoming Investor Conferences
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions
ACHC continues to witness growth in patient days. It authorizes a share repurchase program of almost $300 million.
Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs
MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook
SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.
TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit
Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.
GeneDx Announces Completion of Fabric Genomics Acquisition
Why Investors Were Avoiding GeneDx Holdings Stock This Week
The company crushed analyst estimates in its first quarter, but for many investors it didn't crush them enough. Regardless, several analysts cut their price targets just after the earnings release was published. With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (NASDAQ: WGS) was deep in the doghouse with investors.
GeneDx earnings selloff a buying opportunity, says Craig-Hallum
Craig-Hallum recommends using the post-earnings weakness in shares of GeneDx (WGS) as a buying opportunity. The stock is down over 25% following a “modest” Q1 exome and genome volume miss, which is the company’s first ever sequential decline in volumes, the analyst tells investors in a research note. The firm says management noted Q1 volumes were negatively impacted by significantly worse than expected weather impacts as well as one less day. Encouragingly, GeneDx also saw accelerating volumes i
Hilton price target lowered to $223 from $251 at Truist
Truist lowered the firm’s price target on Hilton (HLT) to $223 from $251 and keeps a Hold rating on the shares after its Q1 results and guidance. The company’s international exposure and new brands help, but the firm has reduced its managed and franchise multiple assumption by 100 bps as Hilton’s C-Corp algorithm looks impaired for now, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> S
Retail Buzz Swirls Around GeneDx As Shares Sink 43% Despite Earnings Beat
GeneDx shares plunged 43% despite strong Q1 results and raised guidance, drawing a surge in retail investor interest. The drop followed the company's first sequential test volume decline, which it linked to weather disruptions.